Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, I…
FAIL · Does not pass the screen
17.99 USD
At the last full screen 2026-08-26
Screened 2026-08-26 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Amneal Pharmaceuticals, Inc. holds its Accumulation at $17.99. Elevated stress, defensive posture warranted, held for 17 days.
As held on the ledger · 2026-08-26
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 17 days
Price at the screen
$17.99
Valuation
37.48 trailing · 15.50 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.26
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
73.11%
Below 33%
Interest-bearing debt is 73.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
32.00%
Below 49%
Money owed to the company is 32.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 29.4% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +17% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Generic Drug Maker Stalls at Modest Valuation
Picture a pharmacy shelf stacked with copies of older medicines. Amneal makes and sells those generics plus a few injectables and specialty lines, yet revenue is expanding just 4% a year while net margins sit at 4%. The shares trade at 15.9 times forward earnings against our fair-value estimate, but the opportunity rating stays at none because growth and profitability give little headroom.
Analyst targets cluster at the current price and the competitive moat remains unknown, so the modest discount offers no real edge once thin returns and slow volume gains are factored in. Ethical screens clear, yet that alone does not turn a low-octane business into an attractive holding.
Risks centre on pricing pressure in generics, regulatory hurdles for new launches and limited cash generation that leaves little buffer if volumes slip further. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-21Markup$18.14+1.6%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-07-21Markup$17.85+10.2%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-07-18Markup$16.20+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-07-17Markup$16.20+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-07-03Markup$16.20+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$16.20Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
